Monograph
J07BH02 - Rota Virus, Pentavalent, Live, Reassorted |
Propably not porphyrinogenic |
PNP |
Side effects
Fever, diarrhea and vomiting are reported as very common side effects.
Rationale
Based on the pharmacokinetics of the rotavirus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live human-bovine rotavirus reassortants.
Therapeutic characteristics
The rotavirus vaccine is indicated for the active immunization of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection. It is administered orally by a 3-dose regimen given with intervals of at least 4 weeks. The first dose may be given from the age of 6 weeks and no later than 12 weeks. The third (last) dose may be given up to the age of 32 weeks, but preferably before the age of 20-22 weeks.
Metabolism and pharmacokinetics
The rotavirus vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Public Assessment Report, RotaTeq (SPC).European Medicines Agency (EMA).
|
|
| 2. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
RotaTeq 
RotaTeq 
Rotateq 
Rotateq 
RotaTeq 
RotaTeq 
RotaTeq 
Rotateq 
RotaTeq 
RotaTeq 
RotaTeq 
RotaTeq
© NAPOS 2025